Tivantinib for the treatment of hepatocellular carcinoma

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011 May 15;128(10):2436–2443.
   PubMed Web of Science ®Google Scholar
• Zheng J, Kuk D, Gonen M, et al. Actual 10-year survivors after resection of hepatocellular carcinoma. Ann Surg Oncol. 2017 May;24(5):1358–1366.
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 2013 Dec;58(6):2023–2031.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 07;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Press release by manufacturer. Available from: http://www.eisai.com/news/enews201706pdf.pdf.
   Google Scholar
• FDA grants priority review for the sNDA for regorafenib in the second-line systemic treatment of liver cancer. The ASCO Post 2017 May 1.
   Google Scholar
• El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015;33(18_suppl):LBA101-LBA101.
   Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18;316(5827):1039–1043.
   PubMed Web of Science ®Google Scholar
• Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692–697.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003 Dec;4(12):915–925.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Zhen Z, Deng DY, et al. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015 Oct 12;34:118.
   PubMed Web of Science ®Google Scholar
• ArQule I. Daiichi Sankyo and ArQule announce the completion of the METIV-HCC phase 3 study of tivantinib in second-line treatment of MET-overexpressing hepatocellular carcinoma. Available from: http://www.businesswire.com/news/home/20170217005132/en/2017.
   Google Scholar
• Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010 Jun;9(6):1544–1553.
   PubMed Web of Science ®Google Scholar
• Basilico C, Pennacchietti S, Vigna E, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res. 2013 May 01;19(9):2381–2392.
   PubMed Web of Science ®Google Scholar
• Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013 May 15;73(10):3087–3096.
   PubMed Web of Science ®Google Scholar
• Rebouissou S, la Bella T, Rekik S, et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro. Clin Cancer Res. 2017 Feb 28;pii: clincanres.3118.2016. DOI:10.1158/1078-0432.CCR-16-3118. [Epub ahead of print].
   PubMedGoogle Scholar
• Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007 Mar 01;67(5):2081–2088.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014 Jun 01;20(11):2959–2970.
   PubMed Web of Science ®Google Scholar
• Zhang SZ, Pan FY, Xu JF, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2005 Oct;4(10):1577–1584.
   PubMed Web of Science ®Google Scholar
• Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem. 2011 Jun 10;286(23):20666–20676.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Senzer N, Mekhail T, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011 Dec 15;17(24):7754–7764.
   PubMed Web of Science ®Google Scholar
• Kubota T, Nishida A, Takeuchi K, et al. Frequency distribution of thiopurine S-methyltransferase activity in red blood cells of a healthy Japanese population. Ther Drug Monit. 2004 Jun;26(3):319–321.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Murakami H, Nishina T, et al. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol. 2013 Jun;24(6):1653–1659.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Aramaki T, Inaba Y, et al. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: distinctive pharmacokinetic profiles from other solid tumors. Cancer Sci. 2015 May;106(5):611–617.
   PubMed Web of Science ®Google Scholar
• Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol. 2011 Apr 01;29(10):1271–1279.
   PubMed Web of Science ®Google Scholar
• Santoro A, Simonelli M, Rodriguez-Lope C, et al. A phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer. 2013 Jan 15;108(1):21–24.
   PubMed Web of Science ®Google Scholar
• Press release from ArQule Inc. [Cited 2014 Jan 16]. Available from: http://investors.arqule.com/releasedetail. cfm?ReleaseID=819847
   Google Scholar
• Goldman JW, Laux I, Chai F, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 01;118(23):5903–5911.
   PubMed Web of Science ®Google Scholar
• Pant S, Saleh M, Bendell J, et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol. 2014 Jul;25(7):1416–1421.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Sosman J, Santoro A, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2015 Feb;33(1):159–168.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Braden AM, Kolesar JM, et al. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2016 Dec 21. DOI:10.1007/s10637-016-0418-8. [Epub ahead of print].
   Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013 Jan;14(1):55–63.
   PubMed Web of Science ®Google Scholar
• Santoro A, Porta C, Rimassa L, et al. Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). J Clin Oncol. 2013;31(suppl;abstr TPS4159).
   PubMed Web of Science ®Google Scholar
• Matsuda-Hashii Y, Takai K, Ohta H, et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Exp Hematol. 2004 Oct;32(10):955–961.
   PubMed Web of Science ®Google Scholar
• Zahir H, Kastrissios H, Carothers T, et al. Exposure-response relationship to assess the risk of neutropenia in patients with hepatocellular carcinoma(HCC) treated with tivantinib. Ann Oncol. 2012;23(9 suppl):ix244.
   Google Scholar
• ArQule [webpage on the Internet]. ArQule provides updates on clinical trials in hepatocellular carcinoma and non-small cell lung cancer with tivantinib (NASDAQ:ARQL). [cited 2016 July 4]. Available from: http://investors.arqule. com/releasedetail.cfm?ReleaseID=819847
   Google Scholar
• Personeni N, Giordano L, Abbadessa G, et al. Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget. 2017 Jan 22. DOI:10.18632/oncotarget.14797. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005 Sep;6(9):669–677.
   PubMed Web of Science ®Google Scholar
• Han Y, Yu Z, Wen S, et al. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat. 2012 Jan;131(2):483–490.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Matsumoto S, Teramukai S, et al. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer. 2007 Jul 02;97(1):37–42.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009 Jul;45(10):1757–1763.
   PubMed Web of Science ®Google Scholar
• Calles A, Kwiatkowski N, Cammarata BK, et al. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol Oncol. 2015 Jan;9(1):260–269.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Bruix J, Broggini M, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET – letter. Clin Cancer Res. 2013 Aug 01;19(15):4290.
   PubMed Web of Science ®Google Scholar